Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC grew its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 7.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 343,064 shares of the biopharmaceutical company's stock after purchasing an additional 22,388 shares during the period. Sanctuary Advisors LLC's holdings in Bristol-Myers Squibb were worth $20,289,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. AlphaCentric Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $1,111,000. Nicholas Hoffman & Company LLC. lifted its stake in shares of Bristol-Myers Squibb by 1.5% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 31,142 shares of the biopharmaceutical company's stock valued at $1,761,000 after purchasing an additional 451 shares during the last quarter. New Jersey Better Educational Savings Trust bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $218,000. Americana Partners LLC bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $12,083,000. Finally, Capital Performance Advisors LLP boosted its holdings in Bristol-Myers Squibb by 24.7% during the 4th quarter. Capital Performance Advisors LLP now owns 6,186 shares of the biopharmaceutical company's stock valued at $350,000 after acquiring an additional 1,225 shares during the period. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

BMY has been the subject of several research analyst reports. Wolfe Research assumed coverage on Bristol-Myers Squibb in a research report on Friday, November 15th. They set a "peer perform" rating for the company. Leerink Partners upgraded shares of Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $55.00 to $73.00 in a report on Tuesday, November 12th. Citigroup upped their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a research note on Wednesday, November 13th. Finally, Truist Financial boosted their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $57.86.

Bristol-Myers Squibb Stock Up 0.1 %

Shares of NYSE:BMY traded up $0.06 during trading on Friday, reaching $55.85. The stock had a trading volume of 11,100,311 shares, compared to its average volume of 10,886,042. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a market capitalization of $113.33 billion, a P/E ratio of -12.63, a PEG ratio of 2.04 and a beta of 0.45. The firm's 50-day simple moving average is $56.99 and its 200 day simple moving average is $54.30. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.44%. The ex-dividend date of this dividend was Friday, January 3rd. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -56.11%.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,823 shares of the stock in a transaction dated Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.09% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.